These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26353772)

  • 1. Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
    Komatsu Y; Ishioka C; Shimada K; Yamada Y; Gamoh M; Sato A; Yamaguchi T; Yuki S; Morita S; Takahashi S; Goto R; Kurihara M
    BMC Cancer; 2015 Sep; 15():626. PubMed ID: 26353772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.
    Miyo M; Kato T; Yoshino T; Yamanaka T; Bando H; Satake H; Yamazaki K; Taniguchi H; Oki E; Kotaka M; Oba K; Miyata Y; Muro K; Komatsu Y; Baba H; Tsuji A
    BMC Cancer; 2020 Jul; 20(1):687. PubMed ID: 32703200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
    Stein A; Glockzin G; Wienke A; Arnold D; Edelmann T; Hildebrandt B; Hollerbach S; Illerhaus G; Königsrainer A; Richter M; Schlitt HJ; Schmoll HJ
    BMC Cancer; 2012 Aug; 12():356. PubMed ID: 22897915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients.
    Parikh RC; Du XL; Robert MO; Lairson DR
    J Manag Care Spec Pharm; 2017 Jan; 23(1):64-73. PubMed ID: 28025930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
    Mishima H; Oba K; Sakamoto J; Muro K; Yoshino T; Hyodo I; Maehara Y
    Jpn J Clin Oncol; 2012 Feb; 42(2):134-8. PubMed ID: 22167662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
    Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
    J Clin Oncol; 2015 Apr; 33(10):1112-8. PubMed ID: 25691669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
    Kusaba H; Esaki T; Futami K; Tanaka S; Fujishima H; Mitsugi K; Sakai K; Ariyama H; Tanaka R; Kinugawa N; Ueki T; Mibu R; Baba E; Nakano S; Akashi K
    Cancer Sci; 2010 Dec; 101(12):2591-5. PubMed ID: 21077997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003.
    Kim TW; Taieb J; Gurary EB; Lerman N; Cui K; Yoshino T
    Future Oncol; 2021 Dec; 17(36):5013-5022. PubMed ID: 34779646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients.
    Ramiscal JA; Jatoi A
    Acta Oncol; 2011 May; 50(4):578-81. PubMed ID: 21108568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
    Blanke CD; Bot BM; Thomas DM; Bleyer A; Kohne CH; Seymour MT; de Gramont A; Goldberg RM; Sargent DJ
    J Clin Oncol; 2011 Jul; 29(20):2781-6. PubMed ID: 21646604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups.
    Macedo LT; da Costa Lima AB; Sasse AD
    BMC Cancer; 2012 Mar; 12():89. PubMed ID: 22414244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer.
    Elshenawy MA; Badran A; Aljubran A; Alzahrani A; Rauf MS; Eldali A; Bazarbashi S
    World J Surg Oncol; 2020 Jul; 18(1):163. PubMed ID: 32641137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    da Silva WC; de Araujo VE; Lima EMEA; Dos Santos JBR; Silva MRRD; Almeida PHRF; de Assis Acurcio F; Godman B; Kurdi A; Cherchiglia ML; Andrade EIG
    BioDrugs; 2018 Dec; 32(6):585-606. PubMed ID: 30499082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
    Matsuda C; Uemura M; Nakata K; Shingai T; Nishimura J; Hata T; Ikenaga M; Takemasa I; Mizushima T; Kato T; Ikeda M; Ohue M; Murata K; Hasegawa J; Satoh T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    BMC Cancer; 2015 Jun; 15():452. PubMed ID: 26036466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001).
    Ozawa M; Watanabe J; Ishibe A; Goto K; Fujii Y; Nakagawa K; Suwa Y; Suwa H; Masui H; Sugita M; Mochizuki Y; Yamagishi S; Hasegawa S; Homma Y; Momiyama M; Kumamoto T; Matsuyama R; Takeda K; Taguri M; Endo I
    Cancer Chemother Pharmacol; 2024 Jun; 93(6):565-573. PubMed ID: 38374403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol.
    Ghanipour L; Jansson Palmer G; Nilsson PJ; Nordenvall C; Frödin JE; Bexe Lindskog E; Asplund D; Swartling T; Graf W; Birgisson H; Syk I; Verwaal V; Brändstedt J; Cashin PH
    PLoS One; 2024; 19(3):e0294018. PubMed ID: 38437211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.
    Tabernero J; Yoshino T; Stintzing S; de Gramont A; Gibbs P; Jonker DJ; Nygren P; Papadimitriou C; Prager GW; Tell R; Lenz HJ
    Cancer Res Commun; 2024 Jan; 4(1):28-37. PubMed ID: 38059497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
    Doi Y; Okada T; Matsumoto H; Ichihara M; Ishida T; Kiwada H
    Cancer Sci; 2010 Nov; 101(11):2470-5. PubMed ID: 20731663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
    Shaojun C; Li H; Haixin H; Guisheng L
    Cancer Biol Ther; 2018 Mar; 19(3):153-159. PubMed ID: 29261002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin.
    Rietveld PCS; Sassen SDT; Guchelaar NAD; van Eerden RAG; de Boer NL; van den Heuvel TBM; Burger JWA; Mathijssen RHJ; Koch BCP; Koolen SLW
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):1006-1016. PubMed ID: 38634204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.